Tonix Pharmaceuticals will present Poster RWD167 at the ISPOR annual meeting on May 20, 2026, showcasing a retrospective cohort study of U.S. fibromyalgia patients based on claims data from April 2021 through April 2024. The session runs from 9:00 to 11:30 a.m. ET, and the poster will be available under Scientific Presentations on Tonix’s website after the event.

TONMYA (cyclobenzaprine HCl sublingual tablets) received FDA approval on August 15, 2025 and entered the U.S. market on November 17, 2025 as the first new fibromyalgia therapy in over 15 years. Key patents on the sublingual formulation are expected to secure U.S. market exclusivity through 2034 or 2035, underpinning long-term revenue potential.

The analysis will characterize treatment patterns, demographics and healthcare utilization among U.S. adults with fibromyalgia using real-world claims data. Insights could inform prescribing trends, payor coverage decisions and identify gaps in existing therapies, potentially bolstering TONMYA adoption.